Developer docs
API playgroundTry for free, no card

Search company profiles

AngioChem

Full company profile

uuid0002u5h

Namestring
AngioChem
Legal namestring
Angiochem Inc.
Websiteurl
angiochem.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

AngioChem is a privately held, clinical-stage biotechnology company founded in 2003 and headquartered in Montreal, Canada. The company is developing a class of engineered peptide-drug and peptide-antibody conjugates built on its proprietary EPiC (Engineered Peptide Compounds) platform technology, which uses the Angiopep-2 peptide vector to deliver therapeutic payloads across the blood-brain barrier via receptor-mediated transcytosis through the LRP-1 pathway — addressing the fundamental challenge that >95% of drugs cannot reach the brain.

The lead asset, ANG1005, is a paclitaxel-Angiopep-2 conjugate that has received FDA Orphan Drug and Fast Track designations for glioblastoma multiforme and was advancing into Phase III clinical trials for leptomeningeal carcinomatosis and brain metastases from HER2-negative breast cancer as of 2019, supported by a $4 million Quebec government loan. The pipeline additionally includes ANG4043 (brain-penetrant anti-HER2 antibody conjugate), ANG2002 (neuropeptide conjugate for pain), ANG1007 and ANG1009 (doxorubicin and etoposide conjugates), and enzyme conjugates such as ANG-EPiC IDUA for lysosomal storage diseases. Clinical efficacy signals include 71% disease control in brain metastases patients and 20-25x higher tumor paclitaxel concentrations versus free drug in patient samples.

AngioChem operates as a partner-dependent drug developer with no commercialized products and no disclosed product revenue. The company's monetization model targets out-licensing and royalties, demonstrated through collaborations with GlaxoSmithKline (LSDs, 2012), Geron (oncology, 2010), and Xinogen (China rights, 2018). Total disclosed equity and debt funding since inception approximates $21 million, with $7.5 million raised in a 2018 Series C and a 2019 government loan backing Phase III work. The company employs 11-50 staff, runs conference-driven scientific engagement (AACR, ASCO, ESMO, San Antonio Breast Cancer Symposium, Society for Neuroscience), and is led by CEO Dr. Jean-Paul Castaigne (MD, MBA) and Executive Chairman John Huss, with Scientific Founder Dr. Richard Béliveau serving as advisor.

Short descriptiontext

AngioChem is a Montreal-based, clinical-stage biotechnology company developing engineered peptide-drug and peptide-antibody conjugates that cross the blood-brain barrier via the LRP-1 pathway (EPiC platform), targeting CNS diseases including brain cancer, brain metastases, pain, and lysosomal storage disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontréal, Canada
HQ citystring
Montréal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-brain barrier delivery, peptide-drug conjugates, CNS therapeutics, brain cancer drug development, LRP-1 receptor targeting
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Drug Development (CNS/Blood-Brain Barrier Delivery)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical-stage Drug Development
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotechnology company developing novel therapeutics. Revenue generation expected through pharmaceutical partnerships, licensing agreements, and eventual product commercialization. Currently focused on advancing ANG1005 through Phase III clinical trials for brain metastases and leptomeningeal carcinomatosis.

angiochem.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AngioChem is a clinical-stage biotechnology company that develops proprietary peptide-drug and peptide-antibody conjugates capable of crossing the blood-brain barrier to treat CNS disorders. Its lead product ANG1005 is an Angiopep-2-paclitaxel conjugate in Phase III development for breast cancer brain metastases and leptomeningeal carcinomatosis, supported by a broader pipeline spanning oncology, pain, and lysosomal storage diseases. Revenue is generated through pharmaceutical licensing and partnership arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 71% disease control rate (15/21 patients) at therapeutic doses with ANG1005 in brain metastases trial
+3 more records
Product overview1 text field

AngioChem is a clinical-stage biotechnology company that has developed a proprietary EPiC (Engineered Peptide Compounds) platform technology centered on Angiopep-2, enabling drugs to cross the blood-brain barrier via the LRP-1 pathway. The product portfolio includes ANG1005 (paclitaxel-peptide conjugate for brain cancer and metastases), ANG4043 (brain-penetrant HER2 antibody conjugate), ANG2002 (neuropeptide conjugate for pain), ANG1007/ANG1009 (doxorubicin/etoposide conjugates), and enzyme conjugates for lysosomal storage diseases. These products range from preclinical to Phase III clinical development stages, targeting CNS diseases including glioblastoma, brain metastases, pain, and lysosomal storage disorders.

Product and service7 records
1ANG1005
CategoryOncology drug conjugate (paclitaxel-peptide)
Description

ANG1005 is a novel paclitaxel-peptide drug conjugate (Angiopep-2-paclitaxel) that leverages the LRP-1 pathway to cross the blood-brain barrier for treatment of brain cancers including glioblastoma multiforme and brain metastases from breast cancer; it has received FDA Orphan Drug and Fast Track designations and entered Phase III for leptomeningeal carcinomatosis from HER2-negative breast cancer.

2ANG4043
CategoryOncology peptide-antibody conjugate
Description

ANG4043 is a brain-penetrant peptide-antibody conjugate of an anti-HER2 monoclonal antibody designed to treat HER2+ breast cancer metastases in the brain, created by conjugating Angiopep-2 to a trastuzumab-like monoclonal antibody.

3ANG2002
CategoryPain management peptide-drug conjugate
Description

ANG2002 is a peptide-drug conjugate using Angiopep-2 linked to neurotensin, developed as a potential first-in-class analgesic drug for cancer pain, post-operative surgery pain, and neuropathic pain without the side effects of opiates.

4ANG1007
CategoryOncology drug conjugate (doxorubicin-peptide)
Description

ANG1007 is an Angiopep-2-conjugated doxorubicin chemotherapeutic designed for increased brain penetration and potential treatment of brain tumors.

5ANG1009
CategoryOncology drug conjugate (etoposide-peptide)
Description

ANG1009 is an Angiopep-2-conjugated etoposide chemotherapeutic designed for increased brain penetration and potential treatment of brain tumors.

6ANG-EPiC IDUA
CategoryLysosomal storage disease enzyme conjugate
Description

ANG-EPiC IDUA is Angiopep-2 conjugated to the iduronidase (IDUA) enzyme, designed to cross the blood-brain barrier to address both systemic and CNS symptoms of Hurler disease (MPS I) and other lysosomal storage diseases.

7EPiC Platform
CategoryDrug delivery platform technology
Description

The EPiC (Engineered Peptide Compounds) platform enables drugs to cross the blood-brain barrier via receptor-mediated transcytosis using the LRP-1 pathway, creating patentable New Chemical Entities including small molecules, peptides, monoclonal antibodies, and siRNA.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Xinogen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-03
Description

License agreement for AngioChem technology. Xinogen received rights to develop and commercialize AngioChem's products in China.

angiochem.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-02-27
Description

Collaboration to discover and develop treatments of lysosomal storage diseases. AngioChem provides its EPiC technology platform to enable enzyme therapies to cross the blood-brain barrier for LSDs with CNS involvement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS-focused company developing therapeutics for neurological conditions. Comparable in clinical-stage CNS specialization and target patient populations, though with different mechanistic approaches.

TypeDirect peer
Description

Clinical-stage biotech developing engineered therapeutics to cross the blood-brain barrier using transferrin receptor (TfR)-based delivery technology. Most direct competitor in BBB-enabled CNS therapeutics with significantly larger capital base.

TypeDirect peer
Description

Specialty biopharmaceutical company developing enzyme replacement and CNS-penetrant therapies for rare diseases including lysosomal storage disorders (MPS I, MPS II, MPS VI), directly comparable to AngioChem's ANG-EPiC IDUA program and broader LSD pipeline.

TypeDirect peer
Description

Prior licensee of ANG1005 (as GRN1005) that conducted Phase 2 trials in brain metastases. Geron represents a previous direct partner and oncology-stage peer with overlapping clinical experience in CNS metastases.

TypeDirect peer
Description

Specialty oncology company developing HER2-targeted therapies (neratinib) for breast cancer, including in patients with CNS metastases. Directly comparable to AngioChem's ANG4043 brain-penetrant anti-HER2 program.

TypeBroad incumbent
Description

Established antibody-drug conjugate (ADC) developer with deep oncology expertise and commercial-stage products. Comparable to AngioChem's brain-penetrant ADC approach and relevant given overlapping payload/cytotoxic agent strategies.

TypeBroad incumbent
Description

Major global pharmaceutical company with industry-leading ADC platform (Enhertu) including HER2-targeted ADCs. Competitor in brain-penetrant ADC space; comparable to ANG4043 and broader AngioChem ADC constructs.

TypeBroad incumbent
Description

Leading oncology company with HER2 franchise (Herceptin, Kadcyla) and active CNS metastases programs. Highly relevant competitor in HER2-positive breast cancer with brain metastases — the same indication space AngioChem is targeting.

9ArmaGen Technologies
TypeDirect peer
Description

BBB delivery biotech using an alternative receptor-mediated transcytosis approach (anti-insulin receptor antibody). Direct peer in BBB-shuttle technology though with a different targeting vector than AngioChem's LRP-1/Angiopep-2.

TypeBroad incumbent
Description

Large pharmaceutical company with significant oncology and neuroscience pipelines including brain-penetrant programs. Potential acquirer/partner for BBB-delivery platform technology; relevant as benchmark for CNS pharma economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AngioChem

Biopharmaceutical Drug Development (CNS/Blood-Brain Barrier Delivery)angiochem.com

AngioChem is a Montreal-based, clinical-stage biotechnology company developing engineered peptide-drug and peptide-antibody conjugates that cross the blood-brain barrier via the LRP-1 pathway (EPiC platform), targeting CNS diseases including brain cancer, brain metastases, pain, and lysosomal storage disorders.

What AngioChem does

AngioChem is a privately held, clinical-stage biotechnology company founded in 2003 and headquartered in Montreal, Canada. The company is developing a class of engineered peptide-drug and peptide-antibody conjugates built on its proprietary EPiC (Engineered Peptide Compounds) platform technology, which uses the Angiopep-2 peptide vector to deliver therapeutic payloads across the blood-brain barrier via receptor-mediated transcytosis through the LRP-1 pathway — addressing the fundamental challenge that >95% of drugs cannot reach the brain.

The lead asset, ANG1005, is a paclitaxel-Angiopep-2 conjugate that has received FDA Orphan Drug and Fast Track designations for glioblastoma multiforme and was advancing into Phase III clinical trials for leptomeningeal carcinomatosis and brain metastases from HER2-negative breast cancer as of 2019, supported by a $4 million Quebec government loan. The pipeline additionally includes ANG4043 (brain-penetrant anti-HER2 antibody conjugate), ANG2002 (neuropeptide conjugate for pain), ANG1007 and ANG1009 (doxorubicin and etoposide conjugates), and enzyme conjugates such as ANG-EPiC IDUA for lysosomal storage diseases. Clinical efficacy signals include 71% disease control in brain metastases patients and 20-25x higher tumor paclitaxel concentrations versus free drug in patient samples.

AngioChem operates as a partner-dependent drug developer with no commercialized products and no disclosed product revenue. The company's monetization model targets out-licensing and royalties, demonstrated through collaborations with GlaxoSmithKline (LSDs, 2012), Geron (oncology, 2010), and Xinogen (China rights, 2018). Total disclosed equity and debt funding since inception approximates $21 million, with $7.5 million raised in a 2018 Series C and a 2019 government loan backing Phase III work. The company employs 11-50 staff, runs conference-driven scientific engagement (AACR, ASCO, ESMO, San Antonio Breast Cancer Symposium, Society for Neuroscience), and is led by CEO Dr. Jean-Paul Castaigne (MD, MBA) and Executive Chairman John Huss, with Scientific Founder Dr. Richard Béliveau serving as advisor.

AngioChem firmographics

Firmographics
Name
AngioChem
Legal name
Angiochem Inc.
Website
https://angiochem.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
AngioChem is a Montreal-based, clinical-stage biotechnology company developing engineered peptide-drug and peptide-antibody conjugates that cross the blood-brain barrier via the LRP-1 pathway (EPiC platform), targeting CNS diseases including brain cancer, brain metastases, pain, and lysosomal storage disorders.
Ownership category
akta.pro rank

AngioChem industry classification

Industry
Product category
Biopharmaceutical Drug Development (CNS/Blood-Brain Barrier Delivery)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Blood-brain barrier delivery
  • Peptide-drug conjugates
  • CNS therapeutics
  • Brain cancer drug development
  • LRP-1 receptor targeting

Where AngioChem is headquartered

Location

Headquarters

HQ city
Montréal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

AngioChem business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical-stage Drug Development: Pre-revenue clinical-stage biotechnology company developing novel therapeutics. Revenue generation expected through pharmaceutical partnerships, licensing agreements, and eventual product commercialization. Currently focused on advancing ANG1005 through Phase III clinical trials for brain metastases and leptomeningeal carcinomatosis.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

AngioChem product offering

Product offering

Core offering

AngioChem is a clinical-stage biotechnology company that develops proprietary peptide-drug and peptide-antibody conjugates capable of crossing the blood-brain barrier to treat CNS disorders. Its lead product ANG1005 is an Angiopep-2-paclitaxel conjugate in Phase III development for breast cancer brain metastases and leptomeningeal carcinomatosis, supported by a broader pipeline spanning oncology, pain, and lysosomal storage diseases. Revenue is generated through pharmaceutical licensing and partnership arrangements.

Product overview

AngioChem is a clinical-stage biotechnology company that has developed a proprietary EPiC (Engineered Peptide Compounds) platform technology centered on Angiopep-2, enabling drugs to cross the blood-brain barrier via the LRP-1 pathway. The product portfolio includes ANG1005 (paclitaxel-peptide conjugate for brain cancer and metastases), ANG4043 (brain-penetrant HER2 antibody conjugate), ANG2002 (neuropeptide conjugate for pain), ANG1007/ANG1009 (doxorubicin/etoposide conjugates), and enzyme conjugates for lysosomal storage diseases. These products range from preclinical to Phase III clinical development stages, targeting CNS diseases including glioblastoma, brain metastases, pain, and lysosomal storage disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • ANG1005 ANG1005 is a novel paclitaxel-peptide drug conjugate (Angiopep-2-paclitaxel) that leverages the LRP-1 pathway to cross the blood-brain barrier for treatment of brain cancers including glioblastoma multiforme and brain metastases from breast cancer; it has received FDA Orphan Drug and Fast Track designations and entered Phase III for leptomeningeal carcinomatosis from HER2-negative breast cancer.
  • ANG4043 ANG4043 is a brain-penetrant peptide-antibody conjugate of an anti-HER2 monoclonal antibody designed to treat HER2+ breast cancer metastases in the brain, created by conjugating Angiopep-2 to a trastuzumab-like monoclonal antibody.
  • ANG2002 ANG2002 is a peptide-drug conjugate using Angiopep-2 linked to neurotensin, developed as a potential first-in-class analgesic drug for cancer pain, post-operative surgery pain, and neuropathic pain without the side effects of opiates.
  • ANG1007 ANG1007 is an Angiopep-2-conjugated doxorubicin chemotherapeutic designed for increased brain penetration and potential treatment of brain tumors.
  • ANG1009 ANG1009 is an Angiopep-2-conjugated etoposide chemotherapeutic designed for increased brain penetration and potential treatment of brain tumors.
  • ANG-EPiC IDUA ANG-EPiC IDUA is Angiopep-2 conjugated to the iduronidase (IDUA) enzyme, designed to cross the blood-brain barrier to address both systemic and CNS symptoms of Hurler disease (MPS I) and other lysosomal storage diseases.
  • EPiC Platform The EPiC (Engineered Peptide Compounds) platform enables drugs to cross the blood-brain barrier via receptor-mediated transcytosis using the LRP-1 pathway, creating patentable New Chemical Entities including small molecules, peptides, monoclonal antibodies, and siRNA.

Quantifiable outcome

  • 71% disease control rate (15/21 patients) at therapeutic doses with ANG1005 in brain metastases trial
  • +3 more outcomes

Companies that use AngioChem

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

AngioChem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AngioChem partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • XinogencoreStrategic or Co-development Partner · 3 January 2018License agreement for AngioChem technology. Xinogen received rights to develop and commercialize AngioChem's products in China.
  • GlaxoSmithKline (GSK)coreStrategic or Co-development Partner · 27 February 2012Collaboration to discover and develop treatments of lysosomal storage diseases. AngioChem provides its EPiC technology platform to enable enzyme therapies to cross the blood-brain barrier for LSDs with CNS involvement.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

AngioChem competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: Clinical-stage CNS-focused company developing therapeutics for neurological conditions. Comparable in clinical-stage CNS specialization and target patient populations, though with different mechanistic approaches.
  • Denali Therapeutics: Clinical-stage biotech developing engineered therapeutics to cross the blood-brain barrier using transferrin receptor (TfR)-based delivery technology. Most direct competitor in BBB-enabled CNS therapeutics with significantly larger capital base.
  • BioMarin Pharmaceutical: Specialty biopharmaceutical company developing enzyme replacement and CNS-penetrant therapies for rare diseases including lysosomal storage disorders (MPS I, MPS II, MPS VI), directly comparable to AngioChem's ANG-EPiC IDUA program and broader LSD pipeline.
  • Geron Corporation: Prior licensee of ANG1005 (as GRN1005) that conducted Phase 2 trials in brain metastases. Geron represents a previous direct partner and oncology-stage peer with overlapping clinical experience in CNS metastases.
  • Puma Biotechnology: Specialty oncology company developing HER2-targeted therapies (neratinib) for breast cancer, including in patients with CNS metastases. Directly comparable to AngioChem's ANG4043 brain-penetrant anti-HER2 program.
  • ArmaGen Technologies: BBB delivery biotech using an alternative receptor-mediated transcytosis approach (anti-insulin receptor antibody). Direct peer in BBB-shuttle technology though with a different targeting vector than AngioChem's LRP-1/Angiopep-2.

Broad incumbents

  • Seagen: Established antibody-drug conjugate (ADC) developer with deep oncology expertise and commercial-stage products. Comparable to AngioChem's brain-penetrant ADC approach and relevant given overlapping payload/cytotoxic agent strategies.
  • Daiichi Sankyo: Major global pharmaceutical company with industry-leading ADC platform (Enhertu) including HER2-targeted ADCs. Competitor in brain-penetrant ADC space; comparable to ANG4043 and broader AngioChem ADC constructs.
  • Genentech (Roche): Leading oncology company with HER2 franchise (Herceptin, Kadcyla) and active CNS metastases programs. Highly relevant competitor in HER2-positive breast cancer with brain metastases — the same indication space AngioChem is targeting.
  • AbbVie: Large pharmaceutical company with significant oncology and neuroscience pipelines including brain-penetrant programs. Potential acquirer/partner for BBB-delivery platform technology; relevant as benchmark for CNS pharma economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AngioChem social profiles

Digital presence

AngioChem compliance and trust

Trust signal

Compliance2 records

AngioChem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AngioChem leadership team

Management profile

Number of profiles

Profiles4 records

AngioChem funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AngioChem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AngioChem

What does AngioChem do?

AngioChem is a clinical-stage biotechnology company that develops proprietary peptide-drug and peptide-antibody conjugates capable of crossing the blood-brain barrier to treat CNS disorders. Its lead product ANG1005 is an Angiopep-2-paclitaxel conjugate in Phase III development for breast cancer brain metastases and leptomeningeal carcinomatosis, supported by a broader pipeline spanning oncology, pain, and lysosomal storage diseases. Revenue is generated through pharmaceutical licensing and partnership arrangements.

Is AngioChem a public or private company?

AngioChem is a private company. It is classified as venture growth investor backed and is currently operating.

When was AngioChem founded?

AngioChem was founded in 2003. It employs 11 to 50 people.

Where is AngioChem based?

AngioChem is headquartered in Montréal, Canada, in the North America region.

How does AngioChem make money?

One revenue line is on record: clinical-stage Drug Development.

Who are AngioChem's main competitors?

Direct peers on record are Sage Therapeutics, Denali Therapeutics, BioMarin Pharmaceutical, Geron Corporation, Puma Biotechnology and ArmaGen Technologies. Broad incumbents are Seagen, Daiichi Sankyo, Genentech (Roche) and AbbVie.

Does AngioChem have an API?

No public API is recorded for AngioChem.

What industry is AngioChem in?

AngioChem's product category is Biopharmaceutical Drug Development (CNS/Blood-Brain Barrier Delivery). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNorth America Leads the Global Peptide Drug Conjugates Market Due to Increased Cancer IncidenceResearchAndMarkets.com published a market analysis report on the global peptide drug conjugates (PDC) sector, projecting market growth to USD 4.21 billion by 2030 with a CAGR of 28.58%, driven by rising cancer incidence globally. The report identifies two FDA-approved PDCs — Novartis's Lutathera and Oncopeptides AB's Pepaxto — and notes that North America led the market in 2022 due to high cancer rates and healthcare professional awareness of novel therapies. Key players including Coherent Biopharma, WuXi STA, Bicycle Therapeutics, AstraZeneca, Cybrexa Therapeutics, Angiochem Inc., and others are actively pursuing strategic initiatives such as partnerships and acquisitions to expand the PDC pipeline.GlobeNewswireAngiochem to Present at SNO Annual MeetingAngiochem will present at the Society of Neuro-Oncology annual meeting in Scottsdale, Arizona, on November 18th. The presentation covers ANG1005, a peptide drug conjugate for recurrent CNS metastasis from breast cancer, with Dr. Santosh Kesari presenting.GlobeNewswireAngiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients With Brain MetastasesAngiochem presented Phase II trial data for ANG1005 at ESMO and EANO 2016, showing clinical benefit and prolonged survival in pretreated breast cancer patients with recurrent brain metastases. The peptide-drug conjugate crossed the blood-brain barrier and was safe, with the company planning a Phase III trial in the new year.GlobeNewswireAngiochem to Present at EANO 2016 MeetingAngiochem will present at the EANO 2016 meeting in Mannheim, Germany, on October 16, 2016. The presentation covers a phase II study of ANG1005, a peptide drug conjugate for leptomeningeal carcinomatosis in breast cancer patients with brain metastases.GlobeNewswireAngiochem to Present at ESMO 2016 CongressAngiochem will present a proffered paper at the ESMO 2016 Congress in Copenhagen on October 7. The presentation covers ANG1005, a peptide-paclitaxel conjugate that crosses the blood-brain barrier and showed activity in patients with recurrent CNS metastasis from breast cancer in a phase II study.GlobeNewswireAngiochem Announces Successful End-of-Phase 2 Meeting With FDA for ANG1005Angiochem announced successful completion of an End-of-Phase 2 meeting with the FDA for ANG1005, a peptide-drug conjugate for leptomeningeal carcinomatosis from breast cancer. The company is preparing to commence Phase 3 trials, with the primary endpoint being overall survival improvement versus Physicians' Best Choice.GlobeNewswireAngiochem's ANG1005 Shows Clinical Benefit and Prolonged Survival in Phase II TrialAngiochem presented data at ASCO 2016 showing its lead compound ANG1005 provided clinical benefit and prolonged survival in pretreated breast cancer patients with recurrent brain metastases and leptomeningeal carcinomatosis. The company plans to advance the drug into advanced clinical studies and meet with the FDA to discuss Phase 2 results.GlobeNewswireAngiochem to Present at ASCO 2016Angiochem will present at ASCO 2016 on June 5 in Chicago, focusing on its peptide-drug conjugate ANG1005 for leptomeningeal carcinomatosis. The company recently announced a scheduled End-of-Phase 2 meeting with the FDA to discuss clinical results and Phase 3 plans.GlobeNewswireAngiochem Announces End-of-Phase 2 Meeting With FDAAngiochem announced the FDA has scheduled an End-of-Phase 2 meeting for its compound ANG1005, to discuss Phase 2 results and plans for a Phase 3 trial. The meeting, set for June 2016, will evaluate study adequacy and safety for proceeding to Phase 3.GlobeNewswireAngiochem Appoints Executive Chairman and Elects New Board of DirectorsAngiochem appointed John Huss as Executive Chairman and elected a new board of directors. The company closed a private financing led by a syndicate of family offices and angels, including BDC Capital. Huss said the financing funds Angiochem's strategic objectives.